Quantum Drug Discovery and the Path to Advantage with Sabrina Maniscalco

Why This Episode Matters

Sabrina Maniscalco is one of the few people in quantum who has lived the full arc: two decades of academic work on open quantum systems and non-Markovian noise at Palermo, Turku, Edinburgh, and Helsinki, followed by founding Algorithmiq with three of her former researchers after an early Qiskit Camp. That trajectory matters now because Algorithmiq just had a landmark stretch — sole winner of the $2M Wellcome Leap Q4Bio prize for a quantum-enabled cancer drug discovery workflow, an €18M Series B, a global HQ move to Milan, and its Tensor Network Error Mitigation (TEM) function landing in IBM's Qiskit Functions catalog.

If you're trying to make sense of where quantum software actually creates value before fault tolerance arrives — and what a credible "trajectory to advantage" looks like when paired with real clients in life sciences — this is a grounded, technically specific conversation with someone building it.

EPISODE SPONSOR

This episode is brought to you by Outshift, Cisco's incubation engine. The need for computational power is rapidly increasing in every sector. From drug discovery to material innovation to complex financial modeling, classical systems are reaching their absolute limits. It's time for a paradigm shift. The answer is a scalable quantum network, built on open standards and vendor-agnostic architecture. By uniting distributed quantum devices, you unlock limitless computational power.

Learn more about the Cisco Universal Quantum Switch at Outshift.com.

Go deeper with the blog post The switch that quantum networking has been waiting for.

What We Get Into

• Why a background in open quantum systems and non-Markovian noise turned out to be unusually well-suited to running algorithms on noisy near-term hardware
• The actual science behind the Q4Bio winning workflow: simulating excited-state dynamics of a photosensitizer drug already in Phase II clinical trials, on up to 100 qubits
• How quantum-boosted DMRG works — and why it gives you a built-in benchmark against the best classical method via the bond dimension
• The tradeoff Sabrina would and wouldn't make between more qubits and lower noise, and why neutral atoms' slower sampling rates matter for chemistry
• Why even fault-tolerant algorithms like quantum phase estimation still depend on getting state initialization and measurement right
• Algorithmiq's two-product structure: the Digital Quantum Interface (hardware-agnostic infrastructure) and the life sciences application framework
• How methods built for chemistry are now opening doors into optimization and GenAI — and why that direction emerged from the work, not from a strategy deck
• What the move from Helsinki to Milan signals about the European quantum ecosystem and Algorithmiq's commercial scale-up
• How an active learning pipeline is already proposing novel drug variants for synthesis in Prof. Sherri McFarland's lab

Resources & Links

Guest & Company

• Algorithmiq — The company Sabrina co-founded with Guillermo García-Pérez, Matteo Rossi, and Boris Sokolov; quantum software for life sciences and chemistry.
• Sabrina Maniscalco — University of Helsinki Research Portal — Publication record covering open quantum systems, non-Markovian dynamics, and quantum information.
• Sabrina Maniscalco — AI for Good Bio — Consolidated bio covering academic roles and advisory positions, including IQOQI Austria and CERN's Quantum Technology Initiative.

The Q4Bio Win

• Algorithmiq Wins $2M Wellcome Leap Q4Bio Prize — Company announcement detailing the photodynamic therapy workflow.
• Wellcome Leap — Q4Bio Prize Announcement — Funder's perspective on finalists and criteria.
• IBM Quantum Blog — Q4Bio Finalists — IBM's account of the workflow and quantum-classical integration.

Funding & HQ Move

• Tech.eu — Algorithmiq's €18M Series B and Milan move — Coverage of Italy's largest quantum VC round to date.
• Quantum Computing Report — Algorithmiq Relocates to Milan — Strategic context including the Q4Bio win and IBM partnership.
• EU-Startups coverage — Investor lineup and Italy's National Quantum Strategy framing.

Quantum Advantage & Tooling

• IBM Quantum Blog — The Dawn of Quantum Advantage — Includes Algorithmiq's TEM (Tensor Network Error Mitigation) function in the Qiskit Functions catalog.
• Algorithmiq & IBM Quantum Advantage Tracker — The heterogeneous materials experiment Algorithmiq and IBM put forward as a community benchmark.
• Silicon Republic interview with Sabrina — Useful prior context on her philosophy of using quantum to simulate quantum systems.

Key Quotes & Insights

• On the foundation of the company's approach: "We learned very early what we thought were the bottlenecks of quantum computers — what you really need to worry about if you want to implement computation at scale." A direct line from Qiskit Camp Vermont to Algorithmiq's product strategy.
• On Q4Bio, in Sabrina's words: "This molecule is already in Phase II clinical trial. So it's not hydrogen. It's a real molecule." A useful counter to the common critique that quantum chemistry demos still live in toy-model land.
• On quantum-boosted DMRG (insight): In the worst case, the method matches the best classical technique; in the better case, it outperforms it — and the bond dimension tells you which regime you're in. Built-in benchmarking against the classical baseline.
• On the hardware tradeoff: Asked whether she'd prefer 100 higher-fidelity qubits or 200 noisier ones, Sabrina's answer is "it depends" — and the explanation about why neutral atoms' lower sampling rates limit chemistry use cases is one of the more concrete things you'll hear on platform tradeoffs.
• On strategy (insight): New verticals at Algorithmiq are ...